Home > Insider Trading > Filing (0000899243-17-027610)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875045	Biogen Inc.	BIIB	Biological Products, (No Disgnostic Substances) (2836)	330112644

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1361754	J Alexander Denner	C/O Sarissa Capital Management Lp 660 Steamboat Road Greenwich CT 06830		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-11-28	20,000	$316.12	403,858	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-11-29	10,000	$319.84	413,858	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	10,029	Direct

Footnotes

On November 28, 2017 and November 29, 2017, funds managed by Sarissa Capital Management LP (such funds, the "Sarissa Funds") purchased an aggregate of 20,000 shares and 10,000 shares, respectively, of common stock of Biogen Inc. All of the shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by the Sarissa Funds.
Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and the managing member of the general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.